Chen, Liang http://orcid.org/0000-0001-6206-1077
Hong, Mengjia
Luan, Changming
Gao, Hongyi
Ru, Gaomeng
Guo, Xinyuan
Zhang, Dujuan
Zhang, Shun
Li, Changwei
Wu, Jun
Randolph, Peyton B.
Sousa, Alexander A.
Qu, Chao
Zhu, Yifan
Guan, Yuting
Wang, Liren
Liu, Mingyao http://orcid.org/0000-0001-7339-5048
Feng, Bo http://orcid.org/0000-0002-4018-3257
Song, Gaojie http://orcid.org/0000-0002-7787-6452
Liu, David R. http://orcid.org/0000-0002-9943-7557
Li, Dali http://orcid.org/0000-0002-0046-8493
Funding for this research was provided by:
National Natural Science Foundation of China (82100773, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023, 32025023)
Foundation for the National Institutes of Health (U01AI142756, U01AI142756, U01AI142756)
Article History
Received: 12 January 2023
Accepted: 8 May 2023
First Online: 15 June 2023
Change Date: 24 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-024-02253-9
Competing interests
: The authors have submitted patent applications based on the results reported in this study (L.C., D.L., M.H. and C.L.). P.R., A.S. and D.R.L. are co-inventors on prime editing patent applications. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics, companies that use or deliver genome editing or genome engineering agents, and owns equity in these companies. The remaining authors declare no competing interests.